JPH08301780A - Fat degradation-promoting agent - Google Patents

Abstract

PURPOSE: To obtain a promoting agent containing a Cirsium plant as an active ingredient, having a clear fat degradation-promoting action in fat tissues, and exhibiting excellent effects on the inhibition, prevention and improvement of obesity. CONSTITUTION: This fat degradation-promoting agent contains a Cirsium plant (preferably Cephalonoplos segetum (Bieb.) Kitam., Cephalonoplos setosum (Biel.) Kitam., Cirsium borealinipponense Kitam., etc.) as an active ingredient. The roots and stems of the Cirsium plant are preferably used, and may be used in the form of the raw state, dry powder solvent extract, etc. The Cirsium plant is preferably compounded in an amount of 0.001-30wt.% converted into the dry product of the solvent extract in the composition on an external preparation and in an amount of 1-2g (converted into the dry product of the solvent extract) per day for an adult on an oral administration preparation. When contained in the external preparation for skin, the objective promoting agent may further be compounded with a xanthine derivative, β-adrenaline action- stimulating medicine, etc.

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to a lipolysis promoter useful for suppressing or preventing obesity, improving obesity constitution, and reducing local or systemic adipose tissue, and a skin external preparation composition containing the same.

[0002]

2. Description of the Related Art Obesity is caused by excessive intake energy with respect to consumed energy, which is accumulated in white adipocytes as neutral fat. It has been pointed out that obesity, which has a large accumulation as visceral fat, is associated with pathological conditions such as insulin resistance and arteriosclerosis, and obesity, which has a large accumulation as subcutaneous fat, is a major problem from a cosmetic perspective regardless of gender. Has become. Conventionally, it has been considered preferable to always drink oolong tea and eucommia tea to suppress, prevent and improve obesity. In addition, dietary restrictions, low-energy foods, appetite suppressants, digestive absorption suppressants and the like have been used for the purpose of suppressing caloric intake. However, the usual drinking of oolong tea and eucommia tea and the suppression of caloric intake do not always have the effect of preventing and improving obesity and are not acceptable as a habit, and they also promote the decomposition of accumulated fat. It wasn't something, so it wasn't a fundamental solution.

[0003]

Therefore, the present invention is intended to provide a lipolysis promoting agent which promotes the decomposition of accumulated adipose tissue and can sufficiently suppress, prevent and improve obesity. is there.

[0004]

[Means for Solving the Problems] In view of such a situation,
As a result of intensive studies conducted by the present inventors, a plant of thistle family, which had not been thought to have a physiological action on adipocytes, was accumulated in adipose tissue during external or oral administration. It has been found that the decomposition of sex fat can be promoted and that obesity can be suppressed, prevented and ameliorated. In addition, xanthine derivative, β-adrenergic stimulant, α ₂
It was found that the above-mentioned action is further enhanced by adding an adrenergic action inhibitor or a bipyridine derivative, and the present invention has been completed.

That is, the present invention provides a lipolysis promoter containing a plant of thistle family. The present invention also provides a skin external preparation containing this lipolysis promoter.

Furthermore, the present invention provides a skin external preparation composition containing a lipolysis promoter and one or more selected from xanthine derivatives, β-adrenergic stimulants, α ₂ -adrenergic inhibitors and bipyridine derivatives. It is provided.

The plant of thistle family used in the present invention includes Cephalon which belongs to the genus Arethia.
oplos segmentum (Bieb.) Kita
m. ), Ezo fox thistle ( Cephalonopl
os setosum (Bieb.) Kitam. );
Cirsium purpur
atum (Maxim.) Matsum. ), Thistle ( Cirsium pendulum Fische
r), thistle ( Cirsium ugoense )
Nakai), Alba Hirea thistle ( Cirsium g
rayanum (Maxim.) Nakai), thistle ( Cirsium kamtschaticum )
Ledeb. ), Thistle ( Cirsium s )
ieboldii Miq. ), Teriha Thistle ( Cir
sium lucens Kitam. ), Cirsium yezoense (Maxim.)
Makino, Sanbethawa Thistle ( Cirsium )
tenuisquamatum Kitam. ), Yellow thistle ( Cirsium tashiroi Ki
tam. ), Thistle ( Cirsium hidae
nse Kitam. ), Oil thistle ( Cirsi
um spinosum Kitam. ), Cirsium thistle ( Cirsium maritimum Makin
o), thistle ( Cirsium brevicau )
le A. Gray), Thrips palmi thistle ( Cirsi )
um boninense Koidz. ), Noazami (Cirsium japonicum DC.), Takasago thistle (Cirsium japonicum
DC. var australe Kitam. ), White thistle ( Cirsium joponi)
cum DC. var Takaoense Kita
m. ), Nora Thistle ( Cirsium oligop
hyllum (Franch. et Savat.) M
atsum. ), Thistle ( Cirsium)
chokaiense Kitam. ), Cirsium borealininipponens
e Kitam. ), Dwarf Lionfish ( Cir
sium okamotoi Kitam. ), Murakumo thistle ( Cirsium maruyama manum
Kitam. ), Water thistle ( Cirsium
diabolicum Kitam. ), Cirsium magofukui Kita
m. ), Yanagia thistle ( Cirsium linear )
e (Thunb.) Sch Bip. ), Cirsium dipsacorepis (Max
im. ) Matsum. ), Thistle ( Cirsi
um kagamontanum Nakai), thistle ( Cirsium suzukiii Kita)
m. ), Gold thistle ( Cirsium gyoj
anum Kitam. ), Koibu thistle ( Cirs
ium confertissimum Naka
i), thistle ( Cirsium bitch
uense Nakai), Eyes thistle ( Cir)
sium aidzuense Nakai), Himeazami (Cirsium buevgeri Mi
q. ), Nagano thistle ( Cirsium long
pedunculatum Kitam. ), Thistle ( Cirsium heianum Koid)
z. ), Thistle ( Cirsium suzuka )
sense Kitam. ), White veil thistle ( C
irsium furusei Kitam. ), White thistle ( Cirsium effusum (Max
im. ) Matsum. ), Hits thistle ( Cirs
ium congestissimum Kita
m. ), Mountain thistle ( Cirsium spicatur
m (Maxim.) Matsum. ), White thistle ( Cirsium tenue Kitam.), Azumayama thistle ( Cirsium microspica)
tum Nakai), thistle ( Cirsium )
inundatum Makino), Norikura Thistle ( Cirsium norikurense Naka)
i), Dakibahimeazami (Cirsium ample
xifolium Kitam. ), Chinese thistle ( Cirsium matsumurae Naka)
i), Cirsium ganjue
nse Kitam. ), Thistle thistle ( Cirsi
um babanum Koidz. var otay
ae (Kitam.)), horse chestnut ( Cirsiu )
m suffultum (Maxim.) Matsu
m. ), Thistle ( Cirsium nippon
icum (Maxim.) Makino), thistle ( Cirsium yakushimense M)
asam. ), Thistle ( Cirsium chik )
Ushiense Koidz. ), Thistle ( Cirsium hanamakiense Kit)
am. ); Cardinals
cripus L. ); Saussurea pulcheila Fisc
her), Spruce japonicus ( Saussurea jap
onica (Thunb.) DC. ), Yukiba Higotai ( Saussurea chionophylla T
akeda), Shiraneazami (Saussurea n
ikoensis Francch et Sava
t. ), Iwategogotai ( Saussurea bra
chycephala French . ), Miyama thistle ( Saussurea franchetii)
Koidz. ), Saussur
ea yanagisawae Takeda), Foriiazami (Saussurea fauriei Fr
anch. ), Yellow thistle ( Saussurea g
racilis Maxim. ), Kirishima Higotai ( S
ausurea scaposa Franch e
t Savet. ); Hemisteptia genus hemisteptia (Hemistepta lyrata Bung
e); Habayamabuchi ( Synurus ) of the genus Yamabuchi
excelsus (Makino) Kitam. ),
Yamabuchi ( Synurus palmatopinn)
atifidus (Makino) Kitam. var
individus Kitam. ), Oyamabokuchi ( Synurus pungens (French e
t Savet. ) Kitam. ); Serratula coronata L.
Subsp. insularis (Iljin) Kit
am. ); Ochera ( Atractylode)
s japonica Koidz. exKit
m. ); Higotai ( Echinops s)
etifler Iljin) and the like. Among these, those of the genus Arechia, thistle and genus Thistle are particularly preferable, and among these, arele thistle, horned fox thistle, horned thistle, mountain thistle, thistle, nora thistle, thistle, octopus thistle and leaf thistle are preferable. In addition, among these plants of the thistle family, Arethia thistle and Noelium thisum have hemostasis, anti-inflammatory and diuretic effects and are known as crude drugs, but none are known to have an action of promoting lipolysis in adipose tissue.

The plants of thistle family in the present invention can be used leaves, head flowers, seeds, stems, roots and whole plants as raw materials, and among them, it is preferable to use roots and stems.

The thistle plant of the present invention is used as a raw material, as a juice, a dry powder, a solvent extract or the like.

Examples of the solvent extract include those extracted with water or an organic solvent such as lower alcohol and polyol, or a mixed solvent thereof, which is used after being appropriately concentrated, purified, sterilized, dried and the like. It

The amount of the thistle plant compounded can be selected from a wide range, although it varies depending on the addition form and administration form. For example, in the case of an external preparation, it is preferable to add 0.005% by weight (hereinafter referred to simply as%) or more, particularly 0.01 to 30%, in terms of a solvent-extracted dry product. Also, in the case of oral preparations, in terms of solvent-extracted dry matter,
It is preferable that the daily dose of an adult is 0.01 to 5 g, especially 1 to 2 g.

The external preparation for skin of the present invention may further contain one or more selected from xanthine derivatives, β-adrenergic stimulants, α ₂ -adrenergic inhibitors and pyridine derivatives. The xanthine derivative used in the present invention is not particularly limited, and for example, the following general formula (1):

[0013]

Embedded image

[In the formula, R ¹ represents a methyl group or a hydrogen atom, R ² represents a hydrogen atom, a hydroxy group having 1 to 2 carbon atoms or an alkanoyl group having 2 to 10 carbon atoms, which may be substituted. To 12 alkyl groups] or a salt thereof.

Examples of such xanthine derivatives include xanthine, aminophylline, theophylline, choline theophylline, caffeine, theobromine, oxtriphylline, diprophylline and proxyphylline. These can be used alone or in combination of two or more. In the present invention, it is preferable to use one kind or a combination of two or more kinds selected from the group consisting of aminophylline, theophylline and caffeine. The content of the xanthine derivative in the composition is preferably 0.005% or more, and particularly preferably 0.01 to 20%. Further, as these xanthine derivatives, those which are substantially purely isolated from plants such as synthetic or tea leaves can be used.

The β-adrenergic stimulant used in the present invention is not particularly limited, and for example, isoproterenol, epinephrine, norepinephrine, dobutamine, dopamine, butopamine, salbutamol, terbutaline, isoethalin, protoxylol, fenoterol, metaproterenol, chlor. Plenalin, Hexoprenaline, Trimethoquinol, Procaterol Hydrochloride, Prenalterol, Forskolin, Disodium (R, R) -5- [2-
[[2- (3-Chlorophenyl) -2-hydroxyethyl] -amino] propyl] -1,3-benzodioxole-2,2-dicarboxylate, (R ^* , R ^* )-4-
[2-({2-[(3-chlorophenyl) -2-hydroxyethyl] amino} propyl) phenyl] phenoxyacetic acid, {2-hydroxy-5- [2-({2-hydroxy-3- [4- ( 1-methyl-4-trifluoromethyl) -1H-imidazol-2-yl] phenoxy} propyl) amino] ethoxy} -benzamide monomethanesulfonate, erythro-DL-1- (7-methylindan-4-yloxy) ) -3-Isopropylaminobutan-2-ol and pharmacologically acceptable salts thereof. Examples of the pharmaceutically acceptable salt include pharmaceutically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts and the like. In the present invention, it is preferable to use one or more selected from the group consisting of isoproterenol, dobutamine, salbutamol and pharmacologically acceptable salts thereof. As the salt in this case, hydrochloride or sulfate is used. Is preferred. The amount of the β-adrenergic stimulant added is 0.
It is preferably 005% or more, and particularly preferably 0.01 to 20%.

The α ₂ adrenergic inhibitor used in the present invention is not particularly limited, and examples thereof include yohimbine, phentolamine, phenoxybenzamine, tolazoline, ergotamine, ergotoxin, dihydroergotamine, ergomethrin, methylergomethrin, dihydroergotoxin, lauorcin, Examples thereof include piperoxane and pharmacologically acceptable salts thereof. Examples of the pharmacologically acceptable salt include those similar to the above. In the present invention, it is preferable to use one or more selected from the group consisting of yohimbine, phentolamine, ergotamine and pharmaceutically acceptable salts thereof, and as the salt in this case, a mesylate salt or a tartrate salt, The hydrochloride salt is preferred. The blending amount of the α ₂ adrenergic inhibitor is preferably 0.005% or more, and particularly preferably 0.01 to 20% in the total amount of the composition.

The bipyridine derivative used in the present invention is not particularly limited, and examples thereof include compounds represented by the following general formula (2) and pharmacologically acceptable salts thereof.

[0019]

Embedded image

[Wherein R ³ is a hydrogen atom or a methyl group,
An alkyl group such as an ethyl group is shown, and Q is NH ₂ , NC, H ₂
Indicates NCO, etc.]

Examples of such bipyridine derivatives include amrinone, milrinone, 5-cyano- [3,4'-bipyridin] -6 (1H) -one and 5-carbamyl- [3,3.
4'-bipyridin] -6 (1H) -one and pharmacologically acceptable salts thereof and the like can be mentioned. Examples of the pharmacologically acceptable salt include the same as those mentioned above. In the present invention, it is preferable to use one kind or two or more kinds selected from the group consisting of amrinone, milrinone, and pharmacologically acceptable salts thereof. The blending amount of the bipyridine derivative is 0.005% or more, especially 0.0
It is preferably 1 to 20%.

In addition to the above-mentioned components, the lipolysis promoter and external skin preparation composition of the present invention include a surfactant, an oily component, which is used in various pharmaceutical and cosmetic preparations.
Moisturizers, polymer compounds, ultraviolet absorbers, anti-inflammatory agents, bactericides, antioxidants, sequestering agents, preservatives, vitamins, pigments, fragrances and the like can be added.

As the above-mentioned surfactant, any of anionic, cationic, nonionic, natural and synthetic surfactants can be used, but in consideration of skin irritation, the nonionic one should be used. Is preferred. Examples of the nonionic surfactant include glycerin fatty acid ester, propylene glycol fatty acid ester, sorbitan fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene sorbit fatty acid ester, polyoxyethylene alkyl ether, polyoxyethylene polyoxypropylene glycol. , Polyoxyethylene polyoxypropylene alkyl ether, polyethylene glycol fatty acid ester, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, alkyl glycoside and the like.

Examples of the oily component include fats and oils, waxes, hydrocarbons, higher fatty acids, higher alcohols, esters, essential oils, silicone oils and the like. Examples of fats and oils include natural fats and oils such as soybean oil, bran oil, jojoba oil, avocado oil, almond oil, olive oil, cacao oil, sesame oil, persic oil, castor oil, coconut oil, mink oil, beef fat, and pork fat. Hydrogenated oil and myristic acid glyceride obtained by hydrogenating natural fats and oils of
Synthetic triglycerides such as 2-ethylhexanoic acid triglyceride; waxes such as carnauba wax, spermaceti, beeswax, lanolin; and hydrocarbons
For example, liquid paraffin, petrolatum, paraffin microcrystalline wax, ceresin, squalane, blistane, etc .; higher fatty acids such as lauric acid,
Myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, linoleic acid, linolenic acid, lanolinic acid, isostearic acid, etc .; higher alcohols such as lauryl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol, lanolin alcohol , Cholesterol, 2-hexyldecanol, etc .; Examples of the esters include cetyl octanoate, triglyceride octanoate, myristyl lactate, cetyl lactate, isopropyl myristate, myristyl myristate, octyldodecyl myristate, isopropyl palmitate, isopropyl adipate, Butyl stearate, decyl oleate, cholesterol isostearate, POE sorbit fatty acid ester and the like; essential oils include, for example, peppermint oil. Jasmine oil, camphor oil, cypress oil, spruce oil, Liu oil, turpentine oil, cinnamon oil,
Bergamot oil, mandarin oil, ginger oil, pine oil, lavender oil, bay oil, clove oil, hiba oil, rose oil, eucalyptus oil, lemon oil, thyme oil, peppermint oil, rose oil, sage oil, menthol, cineole, eugenol. , Citral, citronellal, borneol, linalool, geraniol, camphor, thymol, spilanthol, pinene, limonene, terpene compounds and the like;
Examples of silicone oils include dimethylpolysiloxane. These oily components described above can be used alone or in combination of two or more. In the present invention, among these, myristic acid glyceride, 2
-Ethylhexanoic acid triglyceride, lanolin, liquid paraffin, petrolatum, paraffin microcrystalline wax, squalane, lauric acid, myristic acid, palmitic acid, linoleic acid, linolenic acid, isostearic acid, cetyl alcohol, stearyl alcohol, oleyl alcohol, cholesterol, octane. Acid cetyl, triglyceride octanoate, isopropyl myristyrene, octyldodecyl myristate, cholesterol isostearate, POE sorbit fatty acid ester, peppermint oil, spruce oil, cinnamon oil, rose oil, menthol,
Cineol, eugenol, citral, citronellal, geraniol, pinene, limonene, dimethylpolysiloxane are preferably used.

As the pigments, the pigments listed in Appendix I and II of the tar pigments specified by the Ordinance of the Ministry of Health and Welfare such as Yellow No. 4, Blue No. 1, Yellow No. 202 and the like; as food additives such as chlorophyll, riboflavin, crocin, safflower, anthraquinone Recognized natural pigments and the like: Also, vitamins include vitamin A, vitamin C, vitamin D, vitamin E and the like.

The composition for promoting lipolysis and the external preparation for skin of the present invention can be produced by a conventional method by adding the above-mentioned optional components to the above-mentioned essential components as necessary. In addition, by adding an appropriate amount of water in the range of 0.01 to 90% to the lipolysis promoter and skin external preparation composition of the present invention prepared as described above, the stability of the preparation is increased, or the preparation is prepared. It can also be emulsified.

The lipolysis-promoting agent and the skin external preparation composition of the present invention can be in the form of a bath agent. In this case, the amount used once is in terms of solvent extract dried product of thistle plant. , The concentration in the bath water is 0.01 ppm to 200 ppm, preferably 0.1 to 100 ppm, more preferably 0.5 to
The amount is preferably 50 ppm.

The dosage form of the lipolysis-promoting agent and skin external preparation composition of the present invention is not particularly limited. For example, tablets for oral administration, food, external use, bath, shower, body wash, etc.,
Capsules, liquids, powders, granules, creams, emulsions, gels, pastes, paps, plasters, sticks, sheets, tea bags and the like can be used.

[0029]

The lipolysis-promoting agent and the external skin preparation composition of the present invention have a clear lipolysis-promoting action in adipose tissue, and have excellent effects in suppressing, preventing and improving obesity.

[0030]

The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples. Invention products 1 to 3 and comparative products 1 to 1 used in the examples
3 is as follows.

Inventive Product 1 Cephalonoplos sedge
tum (Bieb.) Kitam. ) Dried root 10
0 g was extracted with hot water by a conventional method, filtered, concentrated under reduced pressure, and then freeze-dried. This was used as an extract of holly thistle.

Inventive product 2 Cephalonoplos sedge
tum (Bieb.) Kitam. ) Dried stem 10
0 g was extracted with a 30% aqueous ethanol solution by a conventional method, filtered, concentrated under reduced pressure, and then freeze-dried. This was used as a holly thistle 30% ethanol extract.

Invention 3 Cirsium japonicum D
C. 100 g of the dried roots of 1) was extracted with hot water by a conventional method, filtered, concentrated under reduced pressure, and then freeze-dried. This was designated as a hot thistle extract.

Comparative Product 1 100 g of dried leaves of oolong tea were extracted with hot water by a conventional method, filtered, concentrated under reduced pressure, and then freeze-dried. This was designated as oolong tea hot water extract.

Comparative product 2 100 g of dried leaves of oolong tea were extracted with a 30% aqueous ethanol solution by a conventional method, filtered, concentrated under reduced pressure, and then freeze-dried. This was designated as an oolong tea 30% ethanol extract.

Comparative Product 3 100 g of dried leaves of Tochu tea were extracted with hot water by a conventional method, filtered, concentrated under reduced pressure, and then freeze-dried. This was designated as Tochu tea hot water extract.

Example 1 Inventive products 1 to 3 and comparative products 1 to 3 were examined for their lipolysis promoting action by the following test method. Table 1 shows the results.

Test Method Rodbell's method [Rodbell, M .; , J. et al. Bio
l. Chem. , 239, 375 (1964)], male Wistar rats (weight 150 to 200 g).
Free adipocytes were prepared from five epididymal adipose tissues using a collagenase solution. Hanks (H) containing bovine serum albumin adjusted to a test substance concentration of 100 μg / ml
The above cells were incubated at 37 ° C. for 2 hours in an ank's) buffer solution, and the released glycerol was subjected to an enzymatic method (F
-Kit glycerol; used by Boehringer Mannheim).

[0039]

[Table 1]

From Table 1, it is possible to measure 100 μl
When g / ml is applied, the invention products 1 to 3 show a clear lipolysis promoting action, whereas the comparative products 1 to 3 do not show this action.

Example 2 A skin external preparation composition having the composition shown in Table 2 was prepared by a conventional method, and its lipolysis promoting action was examined by the following test method. The results are also shown in Table 2.

Test Method The abdominal skin tissue of 5 male Wistar rats (body weight 250-350 g) was peeled together with the subcutaneous fat tissue at a diameter of 4 cm, and set in a cylindrical diffusion cell having a diameter of 2.6 cm. Table 2
0.5 g of the skin external preparation composition shown in 1) was uniformly applied to the skin surface, and the lower cell was filled with Hank's buffer. After standing at 37 ° C. for 3 hours, the glycerol released in the buffer solution in the lower cell was measured by the same enzymatic method as in Example 1.

[0043]

[Table 2]

From Table 2, inventive products 4 to 5 show a clear lipolysis promoting action in subcutaneous adipose tissue when applied to the skin, as compared with comparative product 4 in which the invention products are not blended, and thistle plant Inventive products 6 to 9 in which the extract and the xanthine derivative, β-adrenergic stimulant, α ₂ -adrenergic inhibitor or bipyridine derivative were mixed, the action was further enhanced as compared to Comparative products 5 to 8 in which thistle plant was not mixed. Was done.

Example 3 Oral tablets

[Table 3] (%) Root of thistle root 15 Powder theophylline 10 Lactose 30 Dextrin Appropriate amount Glucose 15 Pigment Trace amount

Example 4 Gel cream

[Table 4] (%) Inventive product 1 extract 15 Liquid paraffin Squalane 20 Microcrystalline wax 5 Cetyl isooctanoate 5 Polyoxyethylene (20) glycerol tri-isostearate 1 Perfume Trace dye Trace

Example 5 Massage Agent with Scrub Agent

[Table 5] (%) Whole thistle powder 10 Isoproterenol hydrochloride 1 Polyethylene beads (particle size 20 μm or less 7%, particle size 5000 μm or more 0%) 10 Liquid paraffin 10 2-Ethylhexanoic acid triglyceride 37 Sorbitol 8 Polyethylene Glycol (average molecular weight 400) 6 Acylmethyl taurine 6 Polyoxyethylene (60) octyldodecyl alcohol ether 8 Purified water Suitable amount Perfume Trace amount

Example 6 Foam pack

[Table 6] (%) Extract of Invention Product 2 10 Yohimbine Hydrochloride 2 1,3-Butylene Glycol 10 Glycerin 10 Methylparaben 0.2 Potassium Hydroxide 0.2 Stearic Acid 1 Butyl Alcohol 2 Polyoxyethylene (60) Hardening Castor oil 3 Liquefied petroleum gas (propellant) 5 Dimethyl ether (propellant) 3 Perfume Trace amount Purified water Appropriate amount

Example 7 Tablet type bath agent

[Table 7] (%) Inventive product 3 extract 14 Amrinone 2 Sodium hydrogen carbonate 20 Sodium carbonate 10 Fumaric acid 30 Polyethylene glycol (average molecular weight 6000) 20 Dextrin Appropriate amount Perfume Trace amount Pigment amount Trace amount

Example 8 Liquid bath agent

[Table 8] (%) Extract of Invention 3 20 Triglyceride octanoate 33 Octyldodecyl myristate 33 Liquid paraffin Appropriate amount Polyoxyethylene sorbit fatty acid ester (40E.O.) 9 Polyoxyethylene sorbit fatty acid ester (20E.O.) ) 3 Fragrance

Continuation of front page (51) Int.Cl. ⁶ Identification number Reference number within the agency FI Technical indication location A61K 7/00 ADA A61K 7/00 ADAK 7/50 7/50 (72) Inventor Satoshi Kanazawa Shellfish, Haga-gun, Tochigi Prefecture 2606 Akabane-cho, Kao Institute of Stock Companies (72) Inventor Yoshinori Nishizawa 2606 Akabane, Kai-cho, Haga-gun, Tochigi Prefecture Kao Institute of Stock Companies

Claims (7)

[Claims] 1. A lipolysis-promoting agent comprising a plant of the thistle group as an active ingredient. 2. A skin external preparation composition containing the lipolysis promoter according to claim 1. 3. The skin external preparation composition according to claim 2, further comprising one or more selected from xanthine derivatives, β-adrenergic stimulants, α ₂ adrenergic inhibitors and bipyridine derivatives. 4. The xanthine derivative is aminophylline,
The external skin preparation composition according to claim 3, which is selected from the group consisting of theophylline, caffeine and salts thereof. 5. The external skin preparation composition according to claim 3, wherein the β-adrenergic stimulant is selected from the group consisting of isoproterenol, dobutamine, salbutamol and salts thereof. 6. The external skin preparation composition according to claim 3, wherein the α ₂ adrenergic inhibitor is selected from the group consisting of yohimbine, phentolamine, ergotamine and salts thereof. 7. The external skin preparation composition according to claim 3, wherein the bipyridine derivative is selected from the group consisting of amrinone, milrinone and salts thereof.